ljc 10627 has been researched along with sulbactam in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Hashizume, T; Hazumi, N; Kato, Y; Matsuda, K | 1 |
Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y | 1 |
5 other study(ies) available for ljc 10627 and sulbactam
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Effects of a beta-lactamase inhibitor, sulbactam, on the activity of carbapenems against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Pseudomonas aeruginosa; Sulbactam; Thienamycins | 1995 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ambroxol; Amlodipine; Anti-Bacterial Agents; Carbapenems; Cefoperazone; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2020 |